PubMed HealthSearch

PubMed · 2916011

Dynamic hepatic CT.

Abstract

A technique for incremental dynamic computed tomography (CT) of the liver with boluses of contrast material (with a 50-g iodine load) administered intravenously is described. For most focal liver lesions, which are hypovascular in relation to normal hepatic parenchyma, bolus contrast material enhancement and incremental dynamic scanning improve detectability, compared with that yielded by nondynamic, contrast material infusion techniques. The bolus contrast-enhanced dynamic scan technique is reproducible and of value in patients undergoing sequential CT for assessment of tumor bulk response to chemotherapy. Patients who are potential candidates for resection of focal hepatic lesions should preoperatively undergo intraarterial contrast-enhanced CT. Intravenous bolus enhanced dynamic hepatic CT can be extended to cover more than one anatomic region (eg, abdomen and thorax), as in patients undergoing CT for staging lung carcinoma. In these patients, incremental scan sequences are programmed caudad to cephalad. Incremental dynamic CT is also an appropriate technique to use in cooperative patients who have suffered blunt abdominal trauma.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W D Foley. 1989. Dynamic hepatic CT.. https://doi.org/10.1148/radiology.170.3.2916011

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Type, severity, frequency and management of adverse reactions associated with ultrasound contrast agents: a systematic review and meta-analysis.

OBJECTIVES: This systematic review and meta-analysis are aimed at evaluating the incidence of adverse drug reactions (ADRs) following administration of clinically approved ultrasound contrast agents (UCAs) in adults and children, to assess risks in patients with cardiovascular disease and in pregnancy, and to evaluate the effectiveness of emergency management of severe ADRs. MATERIALS AND METHODS: A PRISMA 2020 systematic review was conducted searching PubMed, Scopus, and Embase. Two reviewers independently screened, extracted data, and assessed quality. Incidence estimates were pooled when feasible, stratified by age group, contrast agent, and administration route. RESULTS: Seventy-four studies encompassing >&#x2009;1 million adults and >&#x2009;36,000 children were included, contributing multiple analytic cohorts to the quantitative synthesis. Severe acute ADRs were extremely rare (6 and 16 cases per 100,000 in adults and children, respectively) and absent following endocavitary administration in children. Non-severe acute ADRs occurred in 11 and 8 cases per 10,000 adults and children, respectively. Delayed reactions were very rare (<&#x2009;1 case per million in adults). No significant safety differences emerged between UCA products. The incidence of ADRs in patients with cardiovascular disease was analogous to the general population. No ADRs were reported in pregnant women. Standard emergency management was effective in almost all serious cases, though rare fatalities occurred. CONCLUSION: UCAs show an excellent safety profile in adults and children, with very rare severe ADRs and few non-severe, typically self-limiting reactions. Strict adherence to recommended emergency management protocols mitigates the remaining risks, supporting safe use across a broad range of clinical indications. PROSPERO REGISTRATION: CRD42023432668. KEY POINTS: Question What is the incidence, type, and severity of acute and delayed ADRs associated with clinically approved UCAs across different patient populations? Findings Severe acute adverse reactions are very rare, and non-severe reactions are rare and self-limiting, with no significant safety differences between adults, children, or patients with cardiovascular disease. Clinical relevant UCAs show an excellent safety profile across populations. These findings support their safe clinical use as reliable alternatives to iodine-based and gadolinium-based contrast agents in routine diagnostic imaging.

Contrast Media